Inovio will employ this technology to deliver INO-3510, an initial version of its universal SynCon(TM) DNA vaccine
for influenza, consisting of the H5N1 and H1N1 subtypes, in a Phase I clinical trial beginning next year.
NYSE MKT: INO) today unveiled that the company has developed a new DNA-based cytokine immune activator, interleukin -33 (IL-33), that in combination with optimized DNA vaccines
delivered by electroporation increased the potency and efficacy of the therapeutic response to the DNA vaccines
in a preclinical study.
The PowderJect DNA vaccine
proved highly immunogenic, inducing protective levels of antibodies in 80% (n5) of volunteers who had not responded to three doses of commercial vaccine.
Although the DNA vaccine
seems to work, puzzles linger, Griffin says.
are well tolerated and have a remarkable safety profile.
In this monkey trial, vaccinations with INO-5150, Inovio's SynCon(TM) therapeutic DNA vaccine
for prostate cancer, generated strong and robust T cell immune responses.
They noticed, however, that skin cells also absorbed the gene in the dripped DNA vaccine
Inovio's proprietary electroporation-based DNA vaccine
delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses.
Electroporation-based DNA delivery systems have been shown to dramatically increase cellular uptake of a DNA vaccine
and resulting gene expression (i.
Six of the eight monkeys getting the DNA vaccine
produced more antibodies than the two getting the commercial vaccine, study coauthor Donald L.
The session will focus on the advancements made in translating the potential of DNA vaccines
into the clinic as well as the potential benefits of DNA vaccines
vis-a-vis other vaccine platforms in reducing vaccine development times.
Inovio previously collaborated with the UK's University of Southampton and Institute of Cancer Research in a study evaluating a DNA vaccine
for prostate cancer delivered using Inovio's electroporation delivery technology.